89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel–Lindau Disease

Patients with von Hippel–Lindau disease (VHL) are at risk to develop multiple tumors. The growth of lesions is unpredictable, and regular surveillance is critical for early treatment to control local damage. Vascular endothelial growth factor A (VEGF-A) produced locally is supposed to play an important role in development of disease manifestations and is a target for antiangiogenic therapy with the monoclonal antibody bevacizumab. We aimed to assess whether VHL manifestations can be visualized with 89Zr-bevacizumab PET and to explore whether 89Zr-bevacizumab PET can differentiate progressive from nonprogressive lesions. Methods: VHL patients with at least 1 measurable hemangioblastoma were eligible. 89Zr-bevacizumab (37 MBq) was administered intravenously 4 d before the scan. Maximum standardized uptake values were calculated. PET scans were fused with routine MRI of the central nervous system and abdominal MRI or CT. Progressive lesions were defined as new lesions, lesions that became symptomatic, and lesions ≥ 10 mm that increased ≥ 10% and ≥ 4 mm on repeated anatomic imaging within 12 mo. Results: Twenty-two patients were enrolled. At baseline, anatomic imaging showed 311 lesions. 89Zr-bevacizumab PET visualized 59 VHL manifestations, 0–17 per patient. The median of maximum standardized uptake values was 8.5 (range, 1.3–35.8). The detection rate for lesions ≥ 10 mm was 30.8%. Seven additional hotspots without substrate on baseline anatomic imaging were found; 2 were also detected with anatomic imaging during follow-up. Nine of 25 progressive lesions were visible on PET and 27 of 175 nonprogressive lesions, corresponding to a positive predictive value of 25% and a negative predictive value of 90%. SUVmax was similar in progressive and nonprogressive lesions (median, 4.8; range, 0.9–8.9 vs. median, 6.7; range, 1.3–35.8, P = 0.14). Conclusion: VHL manifestations can be visualized with 89Zr-bevacizumab PET with a striking heterogeneity in tracer accumulation. 89Zr-bevacizumab uptake does not predict progression within 12 mo. In one third of the lesions, the drug target VEGF is available and accessible. 89Zr-bevacizumab PET might offer a tool to select VHL patients for anti-VEGF therapy.

[1]  E. D. de Vries,et al.  Molecular Imaging As a Tool for Drug Development and Trial Design. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  V. Zagonel,et al.  First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel–Lindau (VHL) disease: clinical outcome and patterns of radiological response , 2015, Familial Cancer.

[3]  H. Hollema,et al.  89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment , 2015, The Journal of Nuclear Medicine.

[4]  K. Cibulskis,et al.  Sporadic hemangioblastomas are characterized by cryptic VHL inactivation , 2014, Acta neuropathologica communications.

[5]  Francesco Favero,et al.  Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution , 2014, Genome Biology.

[6]  W. Linehan,et al.  Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. , 2014, Journal of neurosurgery.

[7]  S. Richard,et al.  Von Hippel-Lindau: how a rare disease illuminates cancer biology. , 2013, Seminars in cancer biology.

[8]  A. I. Omar Bevacizumab for the treatment of surgically unresectable cervical cord hemangioblastoma: a case report , 2012, Journal of Medical Case Reports.

[9]  M. Weller,et al.  Antiangiogenic Treatment for Multiple CNS Hemangioblastomas , 2012, Oncology Research and Treatment.

[10]  R. Pleijhuis,et al.  89Zr-Bevacizumab PET Imaging in Primary Breast Cancer , 2012, The Journal of Nuclear Medicine.

[11]  Betty Y. S. Kim,et al.  Pazopanib therapy for cerebellar hemangioblastomas in von Hippel–Lindau disease , 2012, Targeted Oncology.

[12]  D. Evans,et al.  Life expectancy in hereditary cancer predisposing diseases: an observational study , 2012, Journal of Medical Genetics.

[13]  G. Fuller,et al.  Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Pilz,et al.  von Hippel–Lindau disease: treatment of retinal haemangioblastomas by targeted therapy with systemic bevacizumab , 2010, Acta ophthalmologica.

[15]  E. Knopp,et al.  Magnetic Resonance Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion Imaging in the Diagnosis of Posterior Fossa Hemangioblastomas and Pilocytic Astrocytomas: Initial Results , 2010, Journal of computer assisted tomography.

[16]  H. Hollema,et al.  VEGF-SPECT with ¹¹¹In-bevacizumab in stage III/IV melanoma patients. , 2010, European journal of cancer.

[17]  Chunwu Zhou,et al.  Angiogenesis of renal cell carcinoma: perfusion CT findings , 2010, Abdominal Imaging.

[18]  I. Sardi,et al.  Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel–Lindau disease , 2009, Pediatric blood & cancer.

[19]  E. Jonasch,et al.  Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. , 2009, The Journal of clinical endocrinology and metabolism.

[20]  V. Dammai,et al.  Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling. , 2008, Cancer research.

[21]  N. Rioux-Leclercq,et al.  Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. , 2007, Human pathology.

[22]  Kentaro Takahashi,et al.  Von Hippel-Lindau Disease , 2024 .

[23]  W. Fiedler,et al.  Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Harris,et al.  Antiangiogenic therapy for von Hippel-Lindau disease. , 2004, JAMA.

[25]  C. Marosi,et al.  Stabilization of a Progressive Hemangioblastoma under Treatment with Thalidomide , 2004, Journal of Neuro-Oncology.

[26]  Sanjiv Sam Gambhir,et al.  AMIDE: a free software tool for multimodality medical image analysis. , 2003, Molecular imaging.

[27]  A. Vortmeyer,et al.  VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. , 1999, Archives of ophthalmology.

[28]  S. Leung,et al.  Expression of vascular endothelial growth factor in von Hippel-Lindau syndrome-associated papillary cystadenoma of the epididymis. , 1998, Human pathology.

[29]  K. Plate,et al.  Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function , 1998 .

[30]  E. Voest,et al.  Elevated ocular levels of vascular endothelial growth factor in patients with von Hippel-Lindau disease. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  K. Plate,et al.  Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.

[32]  T. Sugimura,et al.  Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. , 1994, Cancer research.

[33]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[34]  N. Morton,et al.  Von Hippel-Lindau disease: a genetic study. , 1991, Journal of medical genetics.

[35]  O. Wiestler,et al.  Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus , 1991, The Lancet.

[36]  M. Kosteljanetz,et al.  Von Hippel-Lindau disease (vHL): National clinical guideline for diagnosis and surveillance in Denmark , 2013 .

[37]  L. Tanoue,et al.  Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes , 2012 .

[38]  Yongsheng Huang,et al.  Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease. , 2007, Ophthalmology.

[39]  Y. Katayama,et al.  Clinicopathological study of vascular endothelial growth factor (VEGF), p53, and proliferative potential in familial von Hippel-Lindau disease and sporadic hemangioblastomas , 2006, Brain Tumor Pathology.

[40]  E. Oldfield,et al.  The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. , 2003, Journal of neurosurgery.

[41]  K. Plate,et al.  Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. , 1998, Blood.